New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTSGYP, PRXLSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:45 EDTSGYPSynergy discussing possible sale with advisers, Bloomberg reports
Subscribe for More Information
10:18 EDTSGYPHigh option volume stocks
High option volume stocks: BTX ALL FIVE SGYP SWFT RHT IDCC NVS WGO XBI
10:06 EDTSGYPSynergy Pharmaceuticals talking to advisers about possible sale, Bloomberg says
09:01 EDTPRXLPAREXEL agrees to acquire business assets of Quantum Solutions India
PAREXEL announced that the company has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India, a provider of specialized pharmacovigilance services, based in Chandigarh, India. Pharmacovigilance refers to the collection, detection, assessment, monitoring, and prevention of adverse effects with pharmaceutical products. The acquisition is expected to close in early April of 2015, subject to the satisfaction of closing conditions.
March 16, 2015
18:21 EDTSGYPSynergy Pharmaceuticals reports Q4 EPS (32c), consensus (28c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use